Sugi Predict

Sugi Predict / Compounds / SCHEMBL29476640

SCHEMBL29476640

SCHEMBL29476640

N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 11/20 0.47
▸ NPY1R P25929 6/20 0.47
▸ NPY2R P49146 4/20 0.47
▸ NPY5R Q15761 4/20 0.47
▸ FOLH1 Q04609 1/20 0.45
▸ OPRM1 P35372 1/20 0.41
▸ GNAI3 P08754 1/20 0.41
▸ GNAO1 P09471 1/20 0.41
▸ GNAI1 P63096 1/20 0.41
▸ NOD1 Q9Y239 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29920744 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL6256602 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL29958771 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL29476458 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL6256584 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL5049227 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL30786603 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL29614451 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL31383412 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1
SCHEMBL29430281 1.00 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4711004-A2 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2026-03-18 — — EP disclosed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 — — US disclosed
EP-4618952-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-09-24 — — EP disclosed
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2025-06-19 — — US disclosed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 — — CN disclosed
WO-2025106751-A1 COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE RHYTHM PHARMACEUTICALS, INC. (US) 2025-05-22 — — WO disclosed
EP-4554607-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-05-21 — — EP disclosed
US-12263202-B2 Method of treating melanocortin-4 receptor pathway-associated disorders RHYTHM PHARMACEUTICALS, INC. (US) 2025-04-01 — — US disclosed
US-20250082717-A1 COMPOSITIONS FOR TREATING KIDNEY DISEASE RHYTHM PHARMACEUTICALS INC (US) 2025-03-13 — — US disclosed
WO-2024108198-A2 METHODS OF TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-05-23 — — WO disclosed
US-20240058414-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS RHYTHM PHARMACEUTICALS, INC. 2024-02-22 — — US disclosed
WO-2024015880-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-01-18 — — WO disclosed
EP-4216979-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA SAS (FR) 2022-10-27 — — US disclosed
EP-4029513-A1 MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION Rhythm Pharmaceuticals, Inc. (US) 2022-07-20 — — EP disclosed
EP-3988108-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS Rhythm Pharmaceuticals, Inc. (US) 2022-04-27 — — EP disclosed
WO-2022067086-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS RHYTHM PHARMACEUTICALS, INC. (US) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082717-A1 COMPOSITIONS FOR TREATING KIDNEY DISEASE MC4R, MC2R, MC5R NPY4R 7/4885NPY1R 20/4885NPY2R 12/4885
US-20240058414-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS MC4R, MC5R, MC3R NPY4R 6/4885NPY1R 17/4885NPY2R 10/4885
US-12263202-B2 Method of treating melanocortin-4 receptor pathway-associated disorders MC4R, MC5R, MC3R NPY4R 5/4885NPY1R 26/4885NPY2R 12/4885
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST MC4R, NPY4R, MC3R NPY4R 2/4885NPY1R 8/4885NPY2R 7/4885
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY MC4R, MC1R, MC3R NPY4R 7/4885NPY1R 18/4885NPY2R 19/4885
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS MC4R, MC5R, MC3R NPY4R 5/4885NPY1R 26/4885NPY2R 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback